Shanghai Henlius Biotech, Inc.

  • Market Cap: N/A
  • Industry: Pharmaceuticals & Biotechnology
  • ISIN: CNE100003N76
HKD
76.60
0.7 (0.92%)
  • Price Points
  • Score
  • Mojo Parameters
  • Total Return
  • News and Corporate Actions
  • Key factors
  • Shareholding
  • Financials
  • CompanyCV
stock-recommendationScore
Click here to find our call on this stock
Strong Sell
Sell
Hold
Buy
Strong Buy

Comparison

Company
Score
Quality
Valuation
Financial
Technical
Golden Throat Holdings Group Co., Ltd.
Asymchem Laboratories (Tianjin) Co., Ltd.
Shanghai Henlius Biotech, Inc.
Hua Medicine Ltd.
Immunotech Biopharm Ltd.
Transcenta Holding Ltd.
Abbisko Cayman Ltd.
Zhaoke Ophthalmology Ltd.
CStone Pharmaceuticals Co. Ltd.
3D Medicines, Inc.
China Regenerative Medicine International Ltd.

Why is Shanghai Henlius Biotech, Inc. ?

1
Weak Long Term Fundamental Strength with an average Return on Capital Employed (ROCE) of 5.46%
  • Poor long term growth as Operating profit has grown by an annual rate 23.63% of over the last 5 years
  • High Debt Company with a Debt to Equity ratio (avg) at times
2
With ROE of 27.74%, it has a Very Expensive valuation with a 3.97 Price to Book Value
  • Over the past year, while the stock has generated a return of 125.29%, its profits have risen by 47.8% ; the PEG ratio of the company is 0.3
stock-recommendationReal-Time Research Report

Verdict Report

How much should you sell?

  1. All quantity irrespective of whether you are making profits or losses

(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)

When to re-enter? - We will constantly monitor the company and review our call based on new data

Icon
No Data Found
stock-recommendationQuality
stock-summaryManagement Risk
stock-summaryGrowth
stock-summaryCapital Structure
stock-recommendation
Quality grade scale :

Below Average, Average, Good, Excellent

Quality key factors

Factor
Value
Sales Growth (5y)
56.45%
EBIT Growth (5y)
23.63%
EBIT to Interest (avg)
-4.03
Debt to EBITDA (avg)
2.65
Net Debt to Equity (avg)
0.91
Sales to Capital Employed (avg)
0.66
Tax Ratio
3.00%
Dividend Payout Ratio
0
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
5.46%
ROE (avg)
10.54%
stock-recommendationValuation

Valuation Scorecard stock-summary

stock-recommendation
Valuation grade scale :

Very Risky, Risky, Very Expensive, Expensive, Fair, Attractive, Very Attractive

Valuation Key Factors stock-summary

Factor
Value
P/E Ratio
14
Industry P/E
Price to Book Value
3.97
EV to EBIT
16.66
EV to EBITDA
11.63
EV to Capital Employed
2.56
EV to Sales
2.52
PEG Ratio
0.30
Dividend Yield
NA
ROCE (Latest)
15.34%
ROE (Latest)
27.74%
stock-recommendationTechnicals

Technical key factors

Indicator
Weekly
Monthly
MACD
Bullish
Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bullish
Bullish
Moving Averages
Mildly Bearish (Daily)
KST
Bullish
Bullish
Dow Theory
Mildly Bullish
Mildly Bullish
OBV
No Trend
Mildly Bearish
stock-recommendation Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish  Turned 
Technical Movement
stock-recommendationFinancial Trend

Financial Trend Scorecard stock-summary

stock-recommendation
Financial Trend scale:

Very Negative, Negative, Flat, Positive, Very Positive, Outstanding

10What is working for the Company
INTEREST COVERAGE RATIO(Q)

Highest at 1,211.06

DEBT-EQUITY RATIO (HY)

Lowest at 81.59 %

OPERATING PROFIT(Q)

Highest at HKD 706.85 MM

RAW MATERIAL COST(Y)

Fallen by -10.62% (YoY

OPERATING PROFIT MARGIN(Q)

Highest at 23.34 %

-2What is not working for the Company
INVENTORY TURNOVER RATIO(HY)

Lowest at 1.8 times

DEBTORS TURNOVER RATIO(HY)

Lowest at 4.95 times

Here's what is working for Shanghai Henlius Biotech, Inc.

Interest Coverage Ratio
Highest at 1,211.06 and Grown
In each period in the last five periods
MOJO Watch
The company's ability to manage interest payments is improving

Operating Profit to Interest

Operating Profit
Highest at HKD 706.85 MM and Grown
In each period in the last five periods
MOJO Watch
Near term Operating Profit trend is quite positive

Operating Profit (HKD MM)

Debt-Equity Ratio
Lowest at 81.59 % and Grown
In each half year in the last five Semi-Annual periods
MOJO Watch
The company has been reducing its borrowing as compared to equity capital

Debt-Equity Ratio

Operating Profit Margin
Highest at 23.34 %
in the last five periods
MOJO Watch
Company's profit margin has improved

Operating Profit to Sales

Raw Material Cost
Fallen by -10.62% (YoY)
MOJO Watch
The company's ability to pass on the cost of raw materials to customers has improved; this may lead to a rise in profit margin

Raw Material Cost as a percentage of Sales

Depreciation
Highest at HKD 236.95 MM
in the last five periods
MOJO Watch
The expenditure on assets done by the company may have gone into operation

Depreciation (HKD MM)

Depreciation
At HKD 236.95 MM has Grown at 8.03%
period on period (QoQ)
MOJO Watch
The expenditure on assets done by the company has gone into productive use which should positively reflect in the future sales

Depreciation (HKD MM)

Here's what is not working for Shanghai Henlius Biotech, Inc.

Inventory Turnover Ratio
Lowest at 1.8 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling inventory has slowed

Inventory Turnover Ratio

Debtors Turnover Ratio
Lowest at 4.95 times
in the last five Semi-Annual periods
MOJO Watch
Company's pace of selling Debtors has slowed

Debtors Turnover Ratio